Company Highlights:
Demegen’s drugs are proprietary synthetic and natural peptides (small proteins). Antecedents for these compounds occur in nature as part of the immune system of animals, insects and plants. These new drugs are a powerful new tool to combat bacterial and fungal infections, sexually transmitted diseases and cancer. Generally, the peptides bind to and kill harmful microorganisms and cancer cells.
Demegen’s drugs destroy pathogens that are resistant to existing antibiotics and antifungals. Resistance is becoming a major health problem.
One of the drugs has already been safely administered to over 400 patients.
The Cystic Fibrosis Foundation awarded Demegen $1.5 million for development of a therapy to treat Pseudomonas infections in CF subjects, and a second award to identify a new molecule for B. cepacia.
Funding support for its vaginal microbicide is being provided by the National Institutes of Health.
P113D, the drug for CF, has been awarded Orphan Drug designation by the FDA.
Funding support for the CF product is expected from a large biotechnology company.
Demegen’s peptides also have extensive applications for combating important fungal and bacterial crop diseases and Demegen controls key patents for this use of antimicrobial peptides. Working with USDA and university collaborators, proofs of concept have been shown in several crops.
Outlook:
The Company plans to effect licenses or partnerships that will fund and develop its lead molecules for specific applications.
.
.......According to the Great Pumpkin, ".....You're in .....iHub....., Charlie Brown....."!!!
AI
.......According to the Great Pumpkin, ".....You're in .....iHub....., Charlie Brown....."!!!
